Tools, Modern Drugs, and Latest Investigations for the Diagnosis and Treatment of Heart Failure: A Systematic Review of the General Causes

Year : | Volume : 13 | : | Page : –

    Qhurratul Ain Sayeed

  1. Dr Atika Zainab Sayeed


Heart failure (HF) diagnosis and treatment present formidable challenges, given the absence of a definitive single test. This systematic literature review aims to comprehensively analyze the current landscape of diagnostic tools, modern drugs, and latest investigative approaches in HF management. Recognizing the complexity of HF etiology, this systematic review emphasizes the importance of advanced diagnostic methods, such as genetic testing and artificial intelligence applications. The systematic review was conducted to synthesize evidence on diagnostic and therapeutic strategies for HF. Databases were systematically searched for relevant studies such as PubMed, along with Scopus, along with Web of Science, along with Embase, along with the Cochrane Library. Inclusion criteria included ‘tools’, ‘Heart Failure’, ‘modern drugs’, or ‘latest investigations’ used in the diagnosis or treatment of HF. The selected studies (n=26) were critically appraised for methodological quality. The findings reveal the intricate nature of HF diagnosis, relying on a comprehensive assessment of patient history, physical examinations, imaging studies, and biomarkers. This review emphasizes the role of advanced diagnostic tools and the critical importance of risk markers. Modern drugs, including diuretic agents and digoxin, are discussed for optimal symptom management. Novel therapeutic approaches in advanced clinical stages offer promising avenues for HF treatment.In conclusion, this systematic review provides a nuanced overview of HF management, emphasizing the multifaceted nature of diagnosis and treatment. It underscores the need for ongoing research and innovation to enhance diagnostic accuracy, therapeutic efficacy, and ultimately improve outcomes for individuals with HF. The insights contribute to a foundation for future research directions, fostering a more personalized approach to HF diagnosis and treatment.

Keywords: Heart failure, heart failure diagnosis, heart failure treatment, Diagnostic tools, Modern drugs, Investigative approaches

How to cite this article: Qhurratul Ain Sayeed, Dr Atika Zainab Sayeed Tools, Modern Drugs, and Latest Investigations for the Diagnosis and Treatment of Heart Failure: A Systematic Review of the General Causes rrjomst ; :-
How to cite this URL: Qhurratul Ain Sayeed, Dr Atika Zainab Sayeed Tools, Modern Drugs, and Latest Investigations for the Diagnosis and Treatment of Heart Failure: A Systematic Review of the General Causes rrjomst {cited };:-. Available from:


  1. Topbas C, Swick A, Razavi M, Anderson NL, Pearson TW, Bystrom C. Measurement of lipoprotein-associated phospholipase A2 by use of 3 different methods: exploration of discordance between ELISA and activity assays. Clinical chemistry. 2018 Apr 1;64(4):697-704.
  2. Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W, Krug‐Gourley S. Lipoprotein‐associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease. Journal of the American Heart Association. 2016 Jun 21;5(6):e003407.
  3. Nayeem MA. Role of oxylipins in cardiovascular diseases. Acta Pharmacologica Sinica. 2018 Jul;39(7):1142-54.
  4. Idzikowska K, Zielińska M. Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease. Journal of international medical research. 2018 Aug;46(8):3017-29.
  5. Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. Journal of the American College of Cardiology. 2016 Dec 13;68(23):2577-84.
  6. Karakas M, Schulte C, Appelbaum S, Ojeda F, Lackner KJ, Münzel T, Schnabel RB, Blankenberg S, Zeller T. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study. European heart journal. 2017 Feb 14;38(7):516-23.
  7. Kim AJ, Ro H, Kim H, Chang JH, Lee HH, Chung W, Jung JY. Soluble ST2 and galectin-3 as predictors of chronic kidney disease progression and outcomes. American journal of nephrology. 2021 Apr 15;52(2):119-30.
  8. Li C, Zhao M, Zhao M, Chen N, Guo Y, Du Y, Zhang Y, Cao B, Zhan B, Guo C, Li Y. IL-37 isoform D acts as an inhibitor of soluble ST2 to boost type 2 immune homeostasis in white adipose tissue. Cell Death Discovery. 2022 Apr 5;8(1):163.
  9. Karthigan N, Lockwood S, White A, Yang J, Young MJ. Mineralocorticoid receptor antagonists, heart failure and predictive biomarkers. Journal of Endocrinology. 2022 Jun 1;253(3):R65-76.
  10. Mincarone P, Bodini A, Tumolo MR, Vozzi F, Rocchiccioli S, Pelosi G, Caselli C, Sabina S, Leo CG. Discrimination capability of pretest probability of stable coronary artery disease: a systematic review and meta-analysis suggesting how to improve validation procedures. BMJ open. 2021 Jul 1;11(7):e047677.
  11. Kanmura S, Morinaga Y, Tanaka A, Komaki Y, Iwaya H, Kumagai K, Mawatari S, Sasaki F, Tanoue S, Hashimoto S, Sameshima Y. Increased gene copy number of DEFA1A3 is associated with the severity of ulcerative colitis. Clinical and Translational Gastroenterology. 2021 Apr;12(4).
  12. Deng H, Li J, Shah AA, Lin G, Chen H, Ouyang W. Commonly expressed key transcriptomic profiles of sepsis in the human circulation and brain via integrated analysis. International Immunopharmacology. 2022 Mar 1;104:108518.
  13. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 2012 Oct 20;380(9851):1387-95..
  14. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014 Sep 11;371(11):993-1004.
  15. Pellicori P, Carubelli V, Zhang J, Castiello T, Sherwi N, Clark AL, Cleland JG. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC: Cardiovascular Imaging. 2013 Jan;6(1):16-28..
  16. Hutchinson K, Pellicori P, Dierckx R, Cleland JG, Clark AL. Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine?. Expert Review of Cardiovascular Therapy. 2014 Aug 1;12(8):1025-33..
  17. Pellicori P, Kallvikbacka-Bennett A, Zhang J, Khaleva O, Warden J, Clark AL, Cleland JG. Revisiting a classical clinical sign: jugular venous ultrasound. International journal of cardiology. 2014 Jan 1;170(3):364-70.
  18. Shoaib A, Waleed M, Khan S, Raza A, Zuhair M, Kassianides X, Djahit A, Goode K, Wong K, Rigby A, Clark A. Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. European journal of heart failure. 2014 Dec;16(12):1283-91..
  19. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett Jr JC, Grinfeld L. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. European heart journal. 2013 Mar 14;34(11):835-43.
  20. Sherwi N, Pellicori P, Joseph AC, Buga L. Old and newer biomarkers in heart failure: from pathophysiology to clinical significance. Journal of Cardiovascular Medicine. 2013 Oct 1;14(10):690-7.
  21. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. Journal of the American College of Cardiology. 2001 Apr;37(5):1228-33..
  22. Bayliss J, Norell M, Canepa-Anson RE, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. British heart journal. 1987 Jan;57(1):17.
  23. Francis GS, Siegel RM, Goldsmith SR, OLIVARI MT, LEVINE TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Annals of internal medicine. 1985 Jul 1;103(1):1-6.
  24. Gupta S, Waywell C, Gandhi N, Clayton N, Keevil B, Clark AL, Ng LL, Brooks N, Neyses L. The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction. European journal of heart failure. 2010 Jul;12(7):746-52..
  25. Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M. Diuretic resistance predicts mortality in patients with advanced heart failure. American heart journal. 2002 Jul 1;144(1):31-8..
  26. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). Journal of the American College of Cardiology. 2003 Aug 20;42(4):705-8.
  27. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. The American journal of cardiology. 2006 Jun 15;97(12):1759-64.
  28. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. The American journal of cardiology. 1994 May 1;73(12):881-6.

Subscription Original Research
Received February 1, 2024
Accepted February 6, 2024